EXHIBIT H-25
In re Application of: Fu-Kuen LIN  
Serial No: 675,298  
Filed: November 30, 1984  
For: Production of Erythropoietin  
Examiner: A. Tanenholtz  
Group Art Unit: 194  

I hereby certify that this paper is being deposited with the United States Postal Service as First Class mail in an envelope addressed to: Commissioner of Patents & Trademarks, Washington, D.C. 20231, on this date.

October 20, 1987

Pamela A. Simonton  
Registration No. 31,060  
Attorney for Applicants

TRANSMITTAL

Honorable Commissioner of Patents and Trademarks  
Washington, D.C. 20231

Enclosed is a Declaration as to Deposit of Microorganism for filing in the above referenced case.

Respectfully submitted,

AMGEN INC.

Date 10/20/87

Pamela A. Simonton  
Reg. No. 31,060

Amgen Inc.  
1900 Oak Terrace Lane  
Thousand Oaks, CA 91320  
August 21, 1987

PatFormEl 452 460
Case 1:05-cv-12237-WGY     Document 501-40      Filed 06/14/2007     Page 4 of 7

THE COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20233

Sir:

Transmitted herewith for filing is the patent application of

Inventor: FUKU LIN

For: "PRODUCTION OF ERYTHROPOIETIN"

Filed are:
- Four (4) sheets of drawing.
- An assignment of the invention to ____________________________
- A certified copy of a
- An associate power of attorney
- A verified statement to establish small entity status under 37 CFR 1.9 and 37 CFR 1.27.

The filing fee has been calculated as shown below:

<table>
<thead>
<tr>
<th>(Col. 1)</th>
<th>(Col. 2)</th>
</tr>
</thead>
<tbody>
<tr>
<td>BASIC FEE</td>
<td></td>
</tr>
<tr>
<td>TOTAL CLAIMS</td>
<td>70 - 20 = 50</td>
</tr>
<tr>
<td>INDEP CLAIMS</td>
<td>14 - 3 = 11</td>
</tr>
<tr>
<td>MULTIPLE DEPENDENT CLAIM PRESENTED</td>
<td></td>
</tr>
</tbody>
</table>

If the difference in Col. 1 is less than zero, enter "0" in Col. 2.

☐ Please charge my Deposit Account No. _______ the amount of $______400. A duplicate copy of this sheet is enclosed.

☐ A check in the amount of $665.00 to cover the filing fee is enclosed.

☐ The Commissioner is hereby authorized to charge the following fees associated with this communication credit any overpayment to Deposit Account No. 11-2855.

- Any additional filing fees required under 37 CFR 1.16.
- Any patent application processing fees under 37 CFR 1.17.

☐ The Commissioner is hereby authorized to charge the following fees during the pendency of this application or credit any overpayment to Deposit Account No. ________.

- Any patent application processing fees under 37 CFR 1.17.
- The issue fee set in 37 CFR 1.18 at or before mailing of the Notice of Allowance, pursuant to 37 CFR 1.311(c).
- Any filing fees under 37 CFR 1.16 for presentation of extra claims.

Respectfully submitted,

[Signature]

Michael F. Borun, Reg. No. 25,447
TWO First National Plaza, Suite 2100
Chicago, Illinois 60603
(312) 346-5750

Date: November 27, 1984

461
Best of

Drawings Are Missing
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICATION OF:

SUN-KUEN LIN
Serial No.: 675,298
Filed: November 30, 1984

PRODUCTION OF ERYTHROPOIETIN

GROUP Art Unit

Examiners - A. Tanenholtz

DECLARATION AS TO DEPOSIT OF MICROORGANISM

ROBERT D. WEIST, DECLARES AND SAYS:

1. That he is Secretary of Kirin-Amgen, Inc., the owner of the above-identified patent application;

2. That certain cultures have been deposited in the permanent culture collection of the American Type Culture Collection, 12031 Parklawn Drive, Rockville, Maryland, and the culture deposits meet the requirements of the Budapest Treaty for the purposes of patent procedure;

3. That said cultures were deposited, after the filing date of the above-identified patent application, on October 20, 1987 as accession numbers ATCC 40381, for a deposit of a phage clone designated \( \text{shEL} \) at page 42 of the above-identified application, and ATCC 67545, for a deposit of a clone designated \( \text{pMkE83} \) in \( \text{E. coli} \) as described at page 34 of the above-identified application;

4. That said cultures have been deposited under conditions which ensure that access thereto will be available during the pendency of the above-identified patent application to one determined by the Commissioner to be entitled thereto under 37 C.F.R. 1.14 and 35 U.S.C. 122;

5. That upon issuance of a patent on the above-identified patent application Kirin-Amgen, Inc. will remove any restrictions as to public availability of the culture deposit,
and will replace the same culture deposit should it become

6. That he declares further that all statements made

herein of his own knowledge are true and that all statements made

on information and belief and believed to be true, and further

cultivate life of the

that these statements were made with the knowledge that willful

false statements and the like so made are punishable by fine or

imprisonment, or both, under Section 1001 of Title 18 of the

United States Code, and that such willful false statements may

jeopardize the validity of the application or any patent issuing

thereon.

KIRIN-AMGEN, INC.

BY:

Robert D. Weitz
Secretary

DATED: October 26, 1989